Automation in urine analyzers enable labs to eliminate operator-to-operator variability, and can also make it possible to look at more fields, to quantify results that were previously qualitative.
Emerging nanotechnologies and integrated platforms have the potential to improve diagnosis by direct pathogen detection from urine samples without compromising the sensitivity and specificity of standard methods.
Manufacturers are continually developing new products for urinalysis and intend to deliver a degree of automation that will bring efficiencies and improve turnaround times to reduce labor-intensive and time-consuming urine chemistry analysis.
Automation is affecting the efficiency and accuracy delivered by the new generation urinalysis instruments and hence, the persistent demand for novel urinalysis instruments and consumables.
In a few years - or perhaps more than a few, but in the foreseeable future - urine may again become the specimen of choice for detecting cancer and other diseases with a genetic component, with the next generation of urinalysis analyzers looking more like their immunoassay or chemistry cousins than the traditional urinalysis platform.
For the large pool of opportunities in this sector to be realized, affordable price is an assumption the industry is riding on.
As the demand of hospitals and clinical labs to provide the highest level of care to the patient and the technology a lab utilizes is rising, there seems to be variation in how urinalysis technology fits into full automation.
Urinalysis has been tiptoeing into a new era, using automated urine microscopy and urine chemistry to their full potential.